Evoke Pharma, Inc.

NasdaqCM:EVOK Voorraadrapport

Marktkapitalisatie: US$4.8m

Evoke Pharma Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Evoke Pharma has been growing earnings at an average annual rate of 5%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 67.5% per year.

Belangrijke informatie

5.0%

Groei van de winst

22.2%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie6.0%
Inkomstengroei67.5%
Rendement op eigen vermogen-245.0%
Nettomarge-86.7%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely

Jan 22
Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely

Evoke to get US patent for nasal spray Gimoti

Sep 20

Evoke Pharma Q2 GAAP loss per share narrows, revenue up

Aug 10

Evoke Pharma gets Canadian patent linked to Gimoti nasal spray

Jul 06

Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

Oct 22
Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

Jul 06
Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

Evoke Pharma announces positive findings from second GIMOTI market research study

Jun 15

Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book

Jun 08

Evoke Pharma issued new U.S. patent covering methods of use for Gimoti

Jun 02

Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit

Mar 14
Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit

Opbrengsten en kosten

Hoe Evoke Pharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqCM:EVOK Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 248-7130
31 Mar 246-7130
31 Dec 235-8120
30 Sep 234-8110
30 Jun 234-8110
31 Mar 233-8100
31 Dec 223-8100
30 Sep 222-890
30 Jun 222-890
31 Mar 222-890
31 Dec 212-991
30 Sep 211-991
30 Jun 210-981
31 Mar 210-1476
31 Dec 200-1367
30 Sep 200-1257
30 Jun 200-1248
31 Mar 200-743
31 Dec 190-743
30 Sep 190-743
30 Jun 190-743
31 Mar 190-843
31 Dec 180-844
30 Sep 180-645
30 Jun 180-1047
31 Mar 180-948
31 Dec 170-1247
30 Sep 170-1347
30 Jun 170-1146
31 Mar 170-1346
31 Dec 160-1147
30 Sep 160-1247
30 Jun 160-1248
31 Mar 160-1248
31 Dec 150-1248
30 Sep 150-1249
30 Jun 150-14310
31 Mar 150-14311
31 Dec 140-13310
30 Sep 140-1238
30 Jun 140-935
31 Mar 140-523

Kwaliteitswinsten: EVOK is currently unprofitable.

Groeiende winstmarge: EVOK is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: EVOK is unprofitable, but has reduced losses over the past 5 years at a rate of 5% per year.

Versnelling van de groei: Unable to compare EVOK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: EVOK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


Rendement op eigen vermogen

Hoge ROE: EVOK has a negative Return on Equity (-244.97%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden